Effect of monoamine oxidase inhibitor on the differentiation of malignant glioma cell.
- Author:
Genbao SHAO
1
;
Dandan BO
;
Xiaojuan HAN
;
Qinghua HE
;
Yan ZHANG
;
Jianrong SANG
Author Information
1. School of Medicine, Jiangsu University, Zhenjiang 212013, China. gbshao07@ujs.edu.cn
- Publication Type:Journal Article
- MeSH:
Brain Neoplasms;
pathology;
Cell Line, Tumor;
Cell Transformation, Neoplastic;
drug effects;
Glioma;
pathology;
Histone Deacetylase Inhibitors;
pharmacology;
Humans;
Hydroxamic Acids;
pharmacology;
Monoamine Oxidase Inhibitors;
pharmacology;
Tranylcypromine;
pharmacology
- From:
Journal of Biomedical Engineering
2012;29(3):524-529
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the effect of monoamine oxidase inhibitor tranylcypromine (TCP) on the differentiation of human U251 glioma cells, we treated U251 cells with TCP and/or 100 nmol/L histone deacetylase inhibitor trychostatin A (TSA). The differentiation of U251 cells was observed with inverted microscopy. The cell proliferation and cell cycle distribution were determined by MTT assay and flow cytometry, respectively. Apoptosis was observed by Hoechst 33258 staining. The levels of differentiation-related genes were assessed by real-time PCR and Western blotting. TCP-induced differentiation was characterized by typical morphological changes, inhibition of cellular proliferation, accumulation of cells in the G1 phase of the cell cycle, decreased expression of the pluripotency transcription factors Oct4 and Sox2, and increased expression of glial fibrillary acid protein (GFAP). The combination of TCP and TSA treatment also triggered an over-expression of GFAP. These findings suggest that TCP may induce differentiation of U251 glioma cells, and the differentiation process may be promoted by histone deacetylase inhibitor TSA.
